SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.68), $0.16 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.